Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the New York Yankees rallying to win the World Series as they trailed the Los | ...
The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although BridgeBio ...
2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...
The US Food and Drug Administration (FDA) on Friday approved Attruby (acoramidis), an orally-administered near-complete (≥90% ...
(BBIO), the company announced that its innovative drug, Attruby (acoramidis), has received FDA approval for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). This approval, granted by ...
The U.S. FDA has approved Attruby, a new drug by BridgeBio, for treating a rare heart condition, redefining a market led by ...
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...
The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...
The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...
The U.S. FDA late Friday approved BridgeBio Pharma’s (NASDAQ:BBIO) lead asset Attruby for the rare heart disorder ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback